RT Journal Article
SR Electronic
T1 Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1401
OP 1406
DO 10.21873/anticanres.14897
VO 41
IS 3
A1 ZALYTE, EGLE
A1 DEDONYTE, VERONIKA
A1 KURLINKUS, BENEDIKTAS
A1 SILEIKIS, AUDRIUS
A1 SCHEMMER, PETER
A1 VALIUS, MINDAUGAS
YR 2021
UL http://ar.iiarjournals.org/content/41/3/1401.abstract
AB Background/Aim: Pancreatic ductal adenocarcinoma is one of the deadliest forms of human cancer. Since only a vast panel of cell lines can fully recapitulate disease heterogeneity, our aim was to establish a new pancreatic cancer cell line. Materials and Methods: Newly established pancreatic ductal adenocarcinoma cell line Capan-26 was characterized by assessing growth rate, tumor and stem cell marker expression, colony forming efficiency, mutations of KRAS and TP53 genes, karyotype and sensitivity to drug treatment. Results: Cell doubling time was 74 h. We detected CA19-9, CEACAM6, CD44, OCT4 and ZEB1 expression in Capan-26 cell line. Cells formed colonies in soft agar, have a deletion of KRAS exon 3 and a point mutation V172F in TP53 exon 5. They are a mixed aneuploid/polyploid population with high sensitivity to gemcitabine. Conclusion: Capan-26 is a unique cell line that may be used to study the mechanism of pancreatic cancer.